Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Impact · against what's priced in

Alamar Biosciences gains a significant commercial validation event and product expansion through a national-scale initiative profiling 21,000 plasma samples. The addition of the eMTBR-Tau assay and the open-science data linkage to NACC IDs enhance the platform's visibility and utility in the neurodegenerative disease market.

ALMR+0.60

No priced-in read yet